Columbus Circle Investors trimmed its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 33.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 86,217 shares of the medical research company’s stock after selling 42,966 shares during the quarter. Columbus Circle Investors’ holdings in Bio-Rad Laboratories were worth $20,021,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GW&K Investment Management LLC acquired a new stake in Bio-Rad Laboratories during the third quarter valued at approximately $20,890,000. Vanguard Group Inc boosted its holdings in shares of Bio-Rad Laboratories by 2.0% in the 3rd quarter. Vanguard Group Inc now owns 1,832,968 shares of the medical research company’s stock worth $573,701,000 after acquiring an additional 35,261 shares in the last quarter. Stevens Capital Management LP boosted its holdings in shares of Bio-Rad Laboratories by 62.6% in the 3rd quarter. Stevens Capital Management LP now owns 16,893 shares of the medical research company’s stock worth $5,287,000 after acquiring an additional 6,505 shares in the last quarter. CenturyLink Investment Management Co boosted its holdings in shares of Bio-Rad Laboratories by 15.9% in the 4th quarter. CenturyLink Investment Management Co now owns 4,266 shares of the medical research company’s stock worth $991,000 after acquiring an additional 586 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of Bio-Rad Laboratories by 5.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 4,868 shares of the medical research company’s stock worth $1,524,000 after acquiring an additional 253 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.
BIO stock opened at $261.79 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.49 and a quick ratio of 3.16. Bio-Rad Laboratories, Inc. has a fifty-two week low of $220.05 and a fifty-two week high of $345.15. The company has a market capitalization of $7.63 billion, a P/E ratio of 63.85, a P/E/G ratio of 2.45 and a beta of 1.21.
Several brokerages have recently commented on BIO. Barclays raised Bio-Rad Laboratories from an “equal weight” rating to an “overweight” rating and set a $315.00 target price on the stock in a report on Thursday, January 3rd. Zacks Investment Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Thursday, January 3rd. Finally, Goldman Sachs Group began coverage on Bio-Rad Laboratories in a report on Wednesday, October 17th. They issued a “buy” rating and a $350.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $338.43.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Featured Article: Short Selling Stocks, A Beginner’s Guide
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.